hologic , inc . notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) determination of the measurement date for the market price of acquirer securities issued in a purchase business combination . the components and allocation of the purchase price , consists of the following approximate amounts: .

$ 800: in-process research and development: 10200
developed technology and know how: 39500
customer relationship: 15700
trade name: 3300
order backlog: 800
deferred income taxes: 4400
goodwill: 145900
estimated purchase price: 220600

the company has begun to assess and formulate a plan to restructure certain of r2 2019s historical activities . as of the acquisition date the company recorded a liability of approximately $ 798 in accordance with eitf issue no . 95-3 , recognition of liabilities in connection with a purchase business combination , related to the termination of certain employees and loss related to the abandonment of certain lease space under this plan of which approximately $ 46 has been paid as of september 30 , 2006 . the company believes this plan will be finalized within one year from the acquisition date and will record any additional liabilities at such time resulting in an increase to goodwill . the final purchase price allocations will be completed within one year of the acquisition and any adjustments are not expected to have a material impact on the company 2019s financial position or results of operation . as part of the purchase price allocation , all intangible assets that were a part of the acquisition were identified and valued . it was determined that only customer relationships , trademarks and developed technology had separately identifiable values . customer relationships represent r2 2019s strong active customer base , dominant market position and strong partnership with several large companies . trademarks represent the r2 product names that the company intends to continue to use . developed technology represents currently marketable purchased products that the company continues to resell as well as utilize to enhance and incorporate into the company 2019s existing products . the estimated $ 10200 of purchase price allocated to in-process research and development projects primarily related to r2s digital cad products . the projects are expected to add direct digital algorithm capabilities as well as a new platform technology to analyze images and breast density measurement . the project is approximately 20% ( 20 % ) complete and the company expects to spend approximately $ 3100 over the year to complete . the deferred income tax asset relates to the tax effect of acquired net operating loss carry forwards that the company believes are realizable partially offset by acquired identifiable intangible assets , and fair value adjustments to acquired inventory as such amounts are not deductible for tax purposes . acquisition of suros surgical systems , inc . on july 27 , 2006 , the company completed the acquisition of suros surgical systems , inc. , pursuant to an agreement and plan of merger dated april 17 , 2006 . the results of operations for suros have been included in the company 2019s consolidated financial statements from the date of acquisition as part of its mammography business segment . suros surgical , located in indianapolis , indiana , develops , manufactures and sells minimally invasive interventional breast biopsy technology and products for biopsy , tissue removal and biopsy site marking. .

Questions:
what portion of the estimated purchase price is goodwill?
what portion of the estimated purchase price is developed technology and know how?

Answers:
66%
18%